1484 related articles for article (PubMed ID: 7755066)
1. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intermittent and continuous use of a gonadotropin-releasing hormone antagonist (Nal-Glu) in in vitro fertilization cycles: a preliminary report.
Cassidenti DL; Sauer MV; Paulson RJ; Ditkoff EC; Rivier J; Yen SS; Lobo RA
Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1806-10. PubMed ID: 1750479
[TBL] [Abstract][Full Text] [Related]
3. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
4. Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation.
Frydman R; Cornel C; de Ziegler D; Taieb J; Spitz IM; Bouchard P
Fertil Steril; 1991 Nov; 56(5):923-7. PubMed ID: 1936328
[TBL] [Abstract][Full Text] [Related]
5. [Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial].
Cheng ZX; Kong G; Zhang CL; Zhao YN
Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):9-14. PubMed ID: 32074767
[No Abstract] [Full Text] [Related]
6. Follicular phase gonadotropin-releasing hormone agonist and human gonadotropins: a better alternative for ovulation induction in in vitro fertilization.
Garcia JE; Padilla SL; Bayati J; Baramki TA
Fertil Steril; 1990 Feb; 53(2):302-5. PubMed ID: 2105247
[TBL] [Abstract][Full Text] [Related]
7. An alternate approach to controlled ovarian hyperstimulation in "poor responders": pretreatment with a gonadotropin-releasing hormone analog.
Serafini P; Stone B; Kerin J; Batzofin J; Quinn P; Marrs RP
Fertil Steril; 1988 Jan; 49(1):90-5. PubMed ID: 3121401
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant leuprolide in normal, abnormal, and poor responders to controlled ovarian hyperstimulation for in vitro fertilization/gamete intrafallopian transfer.
Sathanandan M; Warnes GM; Kirby CA; Petrucco OM; Matthews CD
Fertil Steril; 1989 Jun; 51(6):998-1006. PubMed ID: 2498135
[TBL] [Abstract][Full Text] [Related]
9. Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment.
Brzyski RG; Muasher SJ; Droesch K; Simonetti S; Jones GS; Rosenwaks Z
Fertil Steril; 1988 Dec; 50(6):917-21. PubMed ID: 3144467
[TBL] [Abstract][Full Text] [Related]
10. Effect of a gonadotropin-releasing hormone agonist on luteinizing hormone receptors and steroidogenesis in ovarian cells.
Guerrero HE; Stein P; Asch RH; de Fried EP; Tesone M
Fertil Steril; 1993 Apr; 59(4):803-8. PubMed ID: 8458500
[TBL] [Abstract][Full Text] [Related]
11. GnRH agonist and GnRH antagonist protocols in ovarian stimulation: differential regulation pathway of aromatase expression in human granulosa cells.
Khalaf M; Mittre H; Levallet J; Hanoux V; Denoual C; Herlicoviez M; Bonnamy PJ; Benhaim A
Reprod Biomed Online; 2010 Jul; 21(1):56-65. PubMed ID: 20457540
[TBL] [Abstract][Full Text] [Related]
12. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
13. Steroidogenesis of cultured granulosa cells in women at risk for ovarian hyperstimulation syndrome.
Leya JM; Rawlins RG; Radwanska E; Beckmann MW
Fertil Steril; 1992 Dec; 58(6):1153-7. PubMed ID: 1459265
[TBL] [Abstract][Full Text] [Related]
14. Ovulation induction with human menopausal gonadotropin compared to human urinary follicle-stimulating hormone results in a significant shift in follicular fluid androgen levels without discernible differences in granulosa-luteal cell function.
Polan ML; Daniele A; Russell JB; DeCherney AH
J Clin Endocrinol Metab; 1986 Dec; 63(6):1284-91. PubMed ID: 3097055
[TBL] [Abstract][Full Text] [Related]
15. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization.
San Roman GA; Surrey ES; Judd HL; Kerin JF
Fertil Steril; 1992 Oct; 58(4):744-9. PubMed ID: 1426320
[TBL] [Abstract][Full Text] [Related]
16. The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women.
Ditkoff EC; Cassidenti DL; Paulson RJ; Sauer MV; Paul WL; Rivier J; Yen SS; Lobo RA
Am J Obstet Gynecol; 1991 Dec; 165(6 Pt 1):1811-7. PubMed ID: 1750480
[TBL] [Abstract][Full Text] [Related]
17. Administration of human luteinizing hormone (hLH) to macaques after follicular development: further titration of LH surge requirements for ovulatory changes in primate follicles.
Zelinski-Wooten MB; Hutchison JS; Chandrasekher YA; Wolf DP; Stouffer RL
J Clin Endocrinol Metab; 1992 Aug; 75(2):502-7. PubMed ID: 1639951
[TBL] [Abstract][Full Text] [Related]
18. Medroxyprogesterone acetate is a useful alternative to a gonadotropin-releasing hormone antagonist in oocyte donation: a randomized, controlled trial.
Giles J; Alama P; Gamiz P; Vidal C; Badia P; Pellicer A; Bosch E
Fertil Steril; 2021 Aug; 116(2):404-412. PubMed ID: 33814126
[TBL] [Abstract][Full Text] [Related]
19. Effect of growth hormone administration on human ovarian function and steroidogenic gene expression in granulosa-luteal cells.
Tapanainen J; Martikainen H; Voutilainen R; Orava M; Ruokonen A; Rönnberg L
Fertil Steril; 1992 Oct; 58(4):726-32. PubMed ID: 1426317
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
